4//SEC Filing
Loewen Andrea 4
Accession 0000899243-23-019541
CIK 0001358762other
Filed
Sep 25, 8:00 PM ET
Accepted
Sep 26, 4:30 PM ET
Size
15.4 KB
Accession
0000899243-23-019541
Insider Transaction Report
Form 4
Loewen Andrea
SVP, Global Regulatory Affairs
Transactions
- Disposition to Issuer
Employee Stock Option (right to buy)
2023-09-26−11,250→ 0 totalExercise: $196.23Exp: 2030-02-24→ Class A common stock (11,250 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2023-09-26−9,000→ 0 totalExercise: $121.29Exp: 2031-01-04→ Class A common stock (9,000 underlying) - Disposition to Issuer
Class A common stock
2023-09-26−28,416→ 0 total - Disposition to Issuer
Employee Stock Option (right to buy)
2023-09-26−47,738→ 0 totalExercise: $36.71Exp: 2033-01-03→ Class A common stock (47,738 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2023-09-26−35,000→ 0 totalExercise: $27.32Exp: 2032-01-03→ Class A common stock (35,000 underlying)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes,... (Continued in Footnote 2)
- [F2](Continued from Footnote 1) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes.
Documents
Issuer
REATA PHARMACEUTICALS INC
CIK 0001358762
Entity typeother
Related Parties
1- filerCIK 0001591100
Filing Metadata
- Form type
- 4
- Filed
- Sep 25, 8:00 PM ET
- Accepted
- Sep 26, 4:30 PM ET
- Size
- 15.4 KB